The Effect of a Hydrolyzed Polysaccharide Dietary Supplement on Biomarkers in Adults with Nonalcoholic Fatty Liver Disease

Publication:

Evidence-Based Complementary and Alternative Medicine Volume 2018, Article ID 1751583, 10 pages

https://www.hindawi.com/journals/ecam/2018/1751583/

Author(s):

John E. Lewis, Steven E. Atlas, Oscar I. Higuera, Andrea Fiallo, Ammar Rasul, Ashar Farooqi, Olga Kromo, Laura A. Lantigua, Eduard Tiozzo, Judi M. Woolger, Sharon Goldberg, Armando Mendez, Allan E. Rodriguez, and Janet Konefal

Quansys Products Used:

Q-Plex™ Cytokine Kit

Abstract:

The primary objective of the study was to evaluate the effect of a hydrolyzed polysaccharide, Rice Bran Arabinoxylan Compound (RBAC), on biomarkers in adults with nonalcoholic fatty liver disease (NAFLD). A 90-day randomized double-blind placebo-controlled trial examined the effect of RBAC on complete blood count, liver enzymes, lipids, oxidative stress markers, cytokines, and growth factors. Twenty-three adults with NAFLD were enrolled and randomly assigned to one of the two study conditions (n=12 RBAC and n=11 placebo) and consumed 1 gram/day of either compound for 90 days. Subjects were assessed at baseline and 45 and 90 days. No adverse effects were reported. Alkaline phosphatase significantly decreased (−3.1%; SD = 19.9; F[1,19]=5.1, p=0.03) in the RBAC group compared to placebo. Percent monocytes (17.9%; SD = 18.3; F[1,19]=5.9, p=0.02) and percent eosinophils (30.6%; SD = 30.5; F[1,19]=12.3, p value less than 0.01) increased in the RBAC group. IFN-γ (156%; SD = 131.8; F[1,19]=4.2, p=0.06) and IL-18 (29.1%; SD = 64; F[1,19]=5.3, p=0.03) increased in the RBAC group compared to placebo. Other improvements were noted for platelets, neutrophils, neutrophil-lymphocyte ratio, γ-glutamyl transferase, and 4-hydroxynonenal. RBAC had beneficial effects on several biomarkers that add to the known immunomodulatory activities of RBAC, which may be promising for people with NAFLD.